Abstract
To evaluate the feasibility of combining low-dose fractionated whole abdominal radiation (LDF-WAR) with weekly full-dose cisplatin (FD-CDDP) for patients with stage III/IV endometrial carcinoma.
Patients with optimally debulked stage III/IV carcinoma of the endometrium (without extra-abdominal disease) were eligible for the study. Postoperatively, patients received the institutional standard systemic chemotherapy and vaginal brachytherapy. Patients then underwent experimental six weekly cycles of FD-CDDP (40
mg/m
2, maximum 70
mg IV) followed by LDF-WAR 6–8
hours after initiation of chemotherapy. In a conservative design, 6 patients were accrued to two sequential cohorts of LDF-WAR, at 0.5
Gy/fraction [Fx] (total 3
Gy) and 0.75
Gy/Fx (total 4.5
Gy). Toxicities and laboratory studies were evaluated at each visit.
Twelve patients were enrolled from January 2005 to June 2009 with median follow-up of 13.5
months (range: 5–27
months). Seventy-five percent of enrolled patients had uterine papillary serous histology. Eleven patients at least partially completed therapy (range: 2–6 cycles of FD-CDDP/LDF-WAR) with one additional patient opting out at the higher dose level. Combination therapy overall was well tolerated. Three patients in each cohort experienced grade 3 acute hematologic events with one recorded grade 4 toxicity in the second cohort. Of patients receiving any of the experimental treatment, five have experienced recurrences. Three of these patients were in cohort one and received 0.5
Gy/Fx LDF-WAR.
Combination therapy with LDF-WAR as a novel chemopotentiator to FD-CDDP is a feasible adjuvant regimen in optimally debulked patients with stage III/IV endometrial carcinoma. Further investigation is warranted to determine treatment efficacy.
►We evaluate the feasibility of a novel adjuvant treatment regimen for advanced endometrial cancer. ►After systemic chemotherapy, patients receive low-dose fractionated whole abdominal radiation with weekly full-dose cisplatin. ►This regimen is well-tolerated with few dose limiting toxicities.
